Allergic bronchopulmonary aspergillosis

Oct 30, 2017

Pulmatrix Appoints Dr. James Roach as Chief Medical Officer

Oct 18, 2017

Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis

Oct 03, 2017

Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

Sep 05, 2017

Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections